Investigating the effect of CAPRIDIN in the treatment of metabolic fatty liver

Investigation of the Impact of CAPRIDIN Consumption Containing Medium-Chain Fatty Acids on Biochemical Metabolic Pathways and Inflammatory Responses in Individuals Affected by Metabolic Associated Steatotic Liver Disease (MASLD)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170315033086N12

Enrollment

Registered

2024-09-19

Start date

2024-09-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic dysfunction-associated steatotic liver disease. Other specified inflammatory liver diseases, Nonalcoholic steatohepatitis [NASH]

Interventions

Intervention 1: Patients with Metabolic dysfunction–associated steatotic liver disease (MASLD) who, following a comprehensive education session about the composition, on average consume 0.5 millilite

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Individuals diagnosed with Metabolic Associated Steatotic Liver Disease based on laboratory results, imaging techniques, and specialist physician confirmation.

Exclusion criteria

Exclusion criteria: Any previous consumption of the ketogenic diets History of alcohol consumption pregnancy

Design outcomes

Primary

Measure	Time frame
Serum alanine aminotransferase level. Timepoint: One time at the beginning of the study and one time after two months. Method of measurement: Enzymatic method.;Serum level of interleukin 1 beta. Timepoint: One time at the beginning of the study and one time after two months. Method of measurement: Elisa method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Karima

Shahid Beheshti University of Medical Sciences

karima@sbmu.ac.ir+98 21 2387 2570

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Aug 5, 2026